|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Licensing and Alliances in the Asia-Pacific Region - Pharma enhances its focus on APAC markets
Datamonitor, Nov 2010, Pages: 162
While the Japanese market with its increasingly globally-minded pharma companies still dominates deal activities in the Asia-Pacific region, companies and research institutes in the emerging markets of South Korea, China and India reported almost as many deals as Australia during Q3 2009 to Q2 2010.
Features and benefits
- Gain insight into the number and scope of deals and alliances in Asia-Pacific, and key drivers and resistors.
- Identify the most targeted pharmaceutical sectors in terms of deal activity, and which companies have shown the most interest in Asia-Pacific.
- Identify the markets most frequently targeted through licensing and other deal types, and which have attracted the attention of Big Pharma.
Highlights
- Over 300 licensing, market/distribution, research/discovery and other deal types involving APAC-based companies and research institutes were reported between Q3 2009 and Q2 2010. Most were licensing deals and market, promotion and distribution agreements, with the majority targeting territories within APAC.
- Japan signed twice as many deals as most other APAC nations, driven by its large pharmaceutical companies. Australia followed, with its strong research base and biotechnology industry, while South Korea outpaced larger rivals India and China due to a more developed economy and business environment which has attracted international partners.
- Research and development deals will increase as capabilities and capacity in APAC grow, with much of this activity driven by universities and research institutes. Greater flexibility in deal types and structures—including co-promotion agreements and option-based deals—is likely to continue to boost the activity seen in the region.
Your key questions answered
- What are the key drivers and resistors of licensing and other deal activity in the Asia-Pacific region?
- How do trends in deal making differ between the emerging and developed markets in Asia-Pacific?
- Which companies are most active in licensing and alliances in the Asia-Pacific region?
|
|
|
|
